Modest Weight Loss and Reduction in Waist Circumference after Medical Treatment Are Associated with Favorable Changes in Serum Adipocytokines

Metabolism: Clinical and Experimental

Volumn 53, Issue 4, 2004, Pages 430-434

  Valsamakis, G ^b   McTernan, P G ^b   Chetty, R ^b   Al Daghri, N ^b   Field, A ^b   Hanif, W ^b   Barnett, A H ^a   Kumar, S ^b  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; INSULIN; LEPTIN; RESISTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; WEIGHT REDUCTION;

EID: 1842479689     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.11.022     Document Type: Article

References (37)

1. Montague CT, O'Rahilly S: The perils of portliness. Diabetes 49:883-888, 2000
2. Bonora E, Targher G, Alberiche G, et al: Predictors of insulin sensitivity in type 2 diabetes. Diabetic Med 19:535-542, 2002
3. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 119:655-60, 1993
4. Brazilay JL, Abraham L, Heckbert SR: The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study. Diabetes 50:384-389, 2001
5. Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obes 16:397-415, 1992
6. National Institutes of Health, National Heart, Lung, and Blood Institute: Clinical Guideline on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD, National Institutes of Health, 1998
7. Kanders BS, Peterson FJ, Lavin P, et al: Long term health effects associated with significant weight loss: A study of the dose response effect, in Blackburn GL, Kanders BS, (eds): Obesity Pathophysiology, Psychology and Treatment. New York, NY, Chapman & Hall, 1994, pp 167-181
8. Drent ML, van der Veen EA: Lipase inhibition: A novel concept in the treatment of obesity. Int J Obes Relat Metab Disord 17:241-244, 1993
9. Davidson MH, Hauptman J, DiGirolamo M, et al: Weight control and risk reduction in obese subjects treated for 2 years with orlistat. JAMA 281:235-242, 1999
10. Sjostrom L, Rissanen A, Andersen T, et al: Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352:167-172, 1998
11. Bray GA, Blackburn GL, Ferguson GM, et al: Sibutramine produces dose-related weight loss. Obes Res 7:189-198, 1999
12. Funahashi T, Nakamura T, Shimomura I, et al: Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Int Med 38:202-206, 1999
13. Hotamisligil GS, Shargill NS, Spiegelmann BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity linked insulin resistance. Science 259:87-91, 1993
14. Shimomura I, Hammer RE, Ikemoto S, et al: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999
15. Ahren B, Larsson H, Wilhelmsson C: Regulation of circulating leptin levels in humans. Endocrinology 7:1-7, 1997
16. Van Rossum EFC, Nicklas B, Dennis K, et al: Leptin responses to weight loss in postmenopausal women: Relationship to sex-hormone binding globulin and visceral obesity. Obes Res 8:29-35, 2000
17. Ouchi N, Kihara S, Arita Y, et al: Adipocyte derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063, 2001
18. Iwaki M, Matsuda M, Maeda N, et al: Induction of adiponectin, a fat derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003
19. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipocyte-specific protein, adiponectin in obesity. Biochem Biophys Res Commun 257:79-83, 1999
20. Matsuzawa Y, Funahashi T, Nakamura T: Molecular mechanism of metabolic syndrome X: Contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146-154, 1999
21. Ouchi N, Kihara S, Arita Y, et al: Novel modulator for endothelial adhesion molecules: Adipocyte derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
22. Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel adipose specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
23. Yang WS, Lee WL, Funahashi T, et al: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819, 2001
24. Steppan CM, Balley S, Brown E, et al: The hormine resistin links obesity to diabetes. Nature 409:307-312, 2001
25. McTernan CL, McTernan PG, Harte AL, et al: Resistin, central obesity, and type 2 diabetes. Lancet 359:46-47, 2002
26. Kim KH, Lee K, Moon YS, et al: A cysteine rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276:11252-11256, 2001
27. Friedwald WT, Levy RI, Frederickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem 13:499-502, 1972
28. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
29. SPSS: SPSS for Windows. Ed. 10.0.5. Chicago IL, SPSS Inc, 1999
30. Vidal J: Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 26:S25-28, 2002 (suppl)
31. Fujioka K: Management of obesity as a chronic disease: Non-pharmacologic, pharmacologic, and surgical options. Obes Res 10: 116S-123S, 2002 (suppl)
32. Heath MJ, Chong E, Weinstein SP, et al: Sibutramine enhances weight loss and improves glycaemic control and plasma lipid profile in obese patients with type 2 diabetes mellitus. Diabetes 48:A308, 1999 (abstr)
33. Itoh K, Imai K, Masuda T, et al: Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 25:881-886, 2002
34. Torgerson JS, Carlsson B, Stenlof K, et al: A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J Clin Endocrinol Metab 84:4197-4202, 1999
35. Hansen BC, Jen KL, Schwartz J: Changes in insulin responses and binding in adipocytes from monkeys with obesity progressing to diabetes. Int J Obes Relat Metab Disord 12:391-401, 1988
36. Valsamakis G, Chetty R, McTernan PG, et al: Fasting serum adiponectin is lower in Indo-Asians and is related to HDL cholesterol. Diabetes Obesity Metab 5:131-135, 2003
37. Tschritter O, Fritsche A, Thamer C, et al: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239-243, 2003